What is Bellicum Pharmaceuticals Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Bellicum Pharmaceuticals's Average Total Inventories for the quarter that ended in Sep. 2023 was €0.00 Mil. Bellicum Pharmaceuticals's Revenue for the
three
months ended in Sep. 2023 was €0.94 Mil.
Bellicum Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.00.
Bellicum Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2023
stayed the same
from Jun. 2023 (0.00) to Jun. 2023 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bellicum Pharmaceuticals Inventory-to-Revenue Historical Data
The historical data trend for Bellicum Pharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bellicum Pharmaceuticals's Inventory-to-Revenue
For the Biotechnology subindustry, Bellicum Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bellicum Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Bellicum Pharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bellicum Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Bellicum Pharmaceuticals's Days Inventory for the
three
months ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bellicum Pharmaceuticals Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Bellicum Pharmaceuticals (FRA:BPXA) Business Description
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:BPXA has been successfully added to your 